Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2021-11-07 Director's Dealing
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Director's Dealing 2021
Director's Dealing Classification · 100% confidence The document is titled 'Blue Vision A/S – Indberetning af ledende medarbejders transaktion' (Blue Vision A/S – Reporting of leading employee's transaction). It explicitly details a transaction involving shares (A-aktier and B-aktier) by an individual identified as a Director and Board Member ('Direktør og bestyrelsesmedlem'). This content directly matches the definition for Director's Dealing, which is classified under the code DIRS (Report of personal share transactions by company directors and executives (insider trades)). The document is short and specific, confirming the classification.
2021-11-07 Danish
Blue Vision A/S – konvertering af gæld i henhold til konvertible gældsbreve
Share Issue/Capital Change Classification · 100% confidence The document announces the conversion of convertible debt into new shares of Blue Vision A/S. This directly impacts the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2021-10-29 Danish
AGM Information 2021
AGM Information Classification · 99% confidence The document is explicitly titled 'Blue Vision A/S - indkaldelse til ekstraordinær generalforsamling' (Call for Extraordinary General Meeting). It details the date, time, location, and a specific agenda for a shareholder meeting. The agenda includes proposals for board authorization regarding acquisitions (Reponex Pharmaceuticals A/S) and changes to the company's articles of association (vedtægter). This content is characteristic of a formal notice sent to shareholders to solicit their attendance and votes for a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI) or, more specifically given the context of calling a meeting, AGM Information (AGM-R). Since the document is a formal 'indkaldelse' (notice/call) for an *Extraordinary* General Meeting, and it contains the full details necessary for shareholders to prepare for voting (including detailed proposals and voting requirements), AGM-R is the most precise fit, as it covers 'Presentations and materials shared during the Annual General Meeting (AGM)'—a general category that encompasses the formal notice for any general meeting.
2021-10-19 Danish
Blue Vision A/S – Implementering af strategiplanen ved investeringstarget Reponex Pharmaceuticals A/S 
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation for Reponex Pharmaceuticals A/S dated October 19, 2021. It outlines the company's business model, clinical strategy, board of directors, management team, and scientific background. It is structured as a slide-deck-style document intended for potential investors or stakeholders to understand the company's value proposition and operational strategy. It does not contain financial statements, audit results, or specific regulatory filings, but rather serves as a comprehensive overview of the company's business and leadership, which fits the definition of an Investor Presentation.
2021-10-19 Danish
Investor Presentation 2021
Investor Presentation Classification · 99% confidence The document text is a presentation-style document containing background information on a clinical-stage biopharmaceutical company (Reponex Pharmaceuticals A/S), its business model (drug repositioning), key benefits, and company details including management, board members, accountants, and share capital structure. The presence of 'Forward-looking statements' and structured sections typical of an investor briefing strongly suggests this is an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement of a report (RPA/RNS).
2021-10-19 English
M&A Activity 2021
M&A Activity Classification · 98% confidence The document is an official announcement from Blue Vision A/S dated October 19, 2021, detailing a strategic plan to acquire another company, Reponex Pharmaceuticals A/S. It discusses the rationale, the target company's profile, and the transaction conditions, noting that shareholder approval at an upcoming extraordinary general meeting (EGM) is required for the capital increase needed to fund the acquisition. This type of announcement, detailing a significant corporate action like a major investment or acquisition proposal, falls under the scope of M&A Activity (TAR). Although it mentions a future EGM, the primary focus is the proposed transaction itself, not the voting results (DVA) or the proxy materials (PSI). Since it is a detailed announcement of a takeover/acquisition proposal, TAR is the most appropriate classification.
2021-10-19 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.